Sermorelin
GHRH 1-29 fragment
Overview
Sermorelin is the unmodified 29-amino-acid N-terminal fragment of native human GHRH (residues 1-29), retaining the full receptor-binding activity of the parent 44-residue molecule. Approved historically as a prescription drug (Geref) for pediatric GH deficiency diagnosis, Sermorelin is the most studied GHRH-receptor agonist and serves as the reference compound against which engineered analogues (CJC-1295, Tesamorelin, Modified GRF 1-29) are compared. The molecule's clinical pharmacokinetic limitation, a serum half-life of roughly 10-12 minutes due to DPP-4 cleavage at the Tyr1-Ala2 bond, is the design problem that motivated the substitution chemistry behind the CJC-1295 family. Lyochem supplies Sermorelin acetate as a lyophilized powder at ≥99.0% HPLC purity. The 29-residue sequence is within reliable SPPS range and the analytical packet covers peak-integration HPLC, ESI mass spec, water content, and counter-ion. Sermorelin is typically used in research contexts studying GHRH-receptor pharmacology at physiologically relevant time scales (the short half-life is a feature, not a bug, for pulse-pharmacology research) and in compounding workflows where the short-acting profile is appropriate. For sustained-action profiles, buyers generally route to CJC-1295 with DAC instead.
Who buys this, and why
GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology, IGF-axis signalling, and pulse vs. sustained-elevation GH biology. Buyers qualifying a new source typically request sequence verification on the first lot, the counter-ion form (acetate by default), and stability data at −20 °C. Blends — the CJC-1295 + Ipamorelin co-formulated lot is the canonical example — are co-lyophilised rather than solution-mixed so the ratio is locked at the lyophilisation step.
Primary buyer fit: academic and contract research laboratories and research laboratories that have validated this peptide into their workflow.
Specifications
- CAS
- 86168-78-7
- Sequence
- YADAIFTNSYRKVLGQLSARKLLQDIMSR
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 2 mg, 5 mg, 10 mg
- MOQ
- On request
- Lead time
- 7–14 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Counter-ion analysis (acetate vs TFA)
- Stability at −20 °C across 12 months
- Solubility in BAC water / PBS reconstitution
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration, and not supplied to compounding pharmacies — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.
Frequently asked questions
How does Sermorelin compare to CJC-1295 and Tesamorelin?▾
All three are GHRH-receptor agonists, but they differ in their pharmacokinetic engineering. Sermorelin is the unmodified GHRH(1-29) fragment with a roughly 10-minute serum half-life, the native molecule's properties. CJC-1295 (no DAC) adds four amino-acid substitutions that resist DPP-4 cleavage, extending half-life to roughly 30 minutes while retaining the physiological pulsatile signaling pattern. Tesamorelin adds an N-terminal trans-3-hexenoyl group, similarly improving protease resistance and extending half-life, Tesamorelin is the only FDA-approved member of this family, indicated for HIV-associated lipodystrophy. CJC-1295 with DAC sits at the far end of the half-life spectrum at roughly a week via albumin binding.
Why is Sermorelin's short half-life sometimes the preferred property?▾
Research workflows studying GHRH-receptor pharmacology often need to characterize pulsatile signaling at physiologically relevant timescales, sustained-elevation models produce different downstream biology than pulse-pattern models because GH-release feedback loops respond to pulse architecture, not just average exposure. Sermorelin's short half-life makes it the cleanest tool for studying pulse-pharmacology, dose-response within a single GH pulse, and acute receptor pharmacology. For sustained-elevation research or for clinical contexts where convenience matters, the longer-acting CJC-1295 (no DAC) or CJC-1295 with DAC are preferred.
Can Sermorelin be combined with a GHSR-pathway agonist like Ipamorelin?▾
Yes, the GHRH-pathway plus GHSR-pathway combination strategy applies to Sermorelin the same way it applies to CJC-1295: combining a GHRH-receptor agonist with a GHSR agonist produces additive GH-release magnitudes beyond either component alone. The Sermorelin + Ipamorelin combination is less common than CJC-1295 + Ipamorelin in published research and compounding workflows simply because CJC-1295's longer half-life better matches Ipamorelin's, but for short-pulse research applications the Sermorelin combination is mechanistically equivalent.
Related peptides
Buyers who view Sermorelin also ask about:
CJC-1295 (no DAC)
≥99.0%Modified GRF 1-29 · GHRH analog
- CAS
- 863288-34-0
- Vial
- 2 mg–10 mg
Ipamorelin
≥99.0%Ghrelin / GHSR pathway GH-release peptide
- CAS
- 170851-70-4
- Vial
- 2 mg–10 mg
29-mer
Tesamorelin
≥99.0%GHRH analog · approved for HIV-associated lipodystrophy
- CAS
- 218949-48-5
- Vial
- 2 mg–20 mg